DXCM:NGS-DexCom Inc. (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 85.8

Change

0.00 (0.00)%

Market Cap

USD 5.94B

Volume

3.48M

Analyst Target

USD 475.06
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-31 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
PODD Insulet Corporation

-2.05 (-0.64%)

USD 21.86B
MASI Masimo Corporation

+1.76 (+1.08%)

USD 8.49B
BRKR Bruker Corporation

-0.14 (-0.37%)

USD 5.69B
IRTC iRhythm Technologies Inc

+1.40 (+0.97%)

USD 4.49B
TMDX TransMedics Group Inc

+5.78 (+4.45%)

USD 4.11B
PRCT Procept Biorobotics Corp

+3.42 (+5.55%)

USD 3.17B
LIVN LivaNova PLC

+0.37 (+0.83%)

USD 2.40B
QDEL Quidel Corporation

-1.18 (-3.80%)

USD 2.07B
NVCR Novocure Ltd

-0.27 (-1.61%)

USD 1.94B
UFPT UFP Technologies Inc

+3.90 (+1.62%)

USD 1.81B

ETFs Containing DXCM

CYBG:LSE VanEck Bionic Engineering.. 9.88 % 0.00 %

-0.01 (0%)

N/A
EDOC:AU 8.18 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 8.11 % 0.00 %

+0.10 (+0%)

USD 3.28M
CIB0:XETRA VanEck Bionic Engineering.. 8.05 % 0.00 %

+0.03 (+0%)

N/A
CURG:LSE VanEck Genomics and Healt.. 7.81 % 0.00 %

N/A

USD 4.76M
SANE 6.79 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 6.37 % 0.00 %

-0.04 (0%)

N/A
SNSG:LSE Global X Internet of Thin.. 6.29 % 0.00 %

+0.04 (+0%)

USD 2.40M
SN5R:XETRA Global X Internet of Thin.. 5.90 % 0.00 %

+0.04 (+0%)

USD 3.06M
SNSR:SW 5.57 % 0.00 %

N/A

N/A
WELL:PA HAN-GINS Indxx Healthcare.. 5.41 % 0.00 %

-0.01 (0%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 5.41 % 0.00 %

+0.01 (+0%)

N/A
FDOC:LSE 4.89 % 0.00 %

N/A

N/A
MEDI Harbor Health Care ETF 4.63 % 0.00 %

+0.12 (+0%)

USD 0.01B
DIP 4.61 % 0.00 %

N/A

N/A
EDOC:LSE Global X Telemedicine & D.. 4.59 % 0.00 %

+0.06 (+0%)

USD 4.27M
EDOG:LSE Global X Telemedicine & D.. 4.59 % 0.00 %

+0.03 (+0%)

USD 0.30M
FDHT:XETRA 4.55 % 0.00 %

N/A

N/A
DDOC:F Global X Telemedicine & D.. 4.33 % 0.00 %

+0.13 (+0%)

N/A
FDHT Fidelity Covington Trust .. 4.14 % 0.00 %

+0.02 (+0%)

USD 8.09M
UMDV:SW iShares US Medical Device.. 4.00 % 0.00 %

N/A

N/A
HLTH:AU Vaneck Global Healthcare .. 2.73 % 0.00 %

-0.11 (0%)

USD 0.06B
ESGX 2.29 % 0.00 %

N/A

N/A
RSPH Invesco S&P 500 Equal Wei.. 2.04 % 0.00 %

-0.05 (0%)

USD 0.75B
AVMV American Century ETF Trus.. 1.27 % 0.00 %

-0.09 (0%)

USD 0.19B
BFIT 0.00 % 0.50 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.21 (+0%)

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
QQXT First Trust NASDAQ-100 Ex.. 0.00 % 0.60 %

-0.57 (0%)

USD 1.11B
GDNA 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
SNSR Global X Internet of Thin.. 0.00 % 0.69 %

-0.24 (0%)

USD 0.22B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

+0.43 (+0%)

USD 0.17B
DBPD:F Xtrackers - ShortDAX x2 D.. 0.00 % 0.00 %

N/A

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.01 (0%)

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.04B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

+0.03 (+0%)

N/A
DTEC ALPS Disruptive Technolog.. 0.00 % 0.00 %

-0.05 (0%)

USD 0.08B
IMCG iShares Morningstar Mid-C.. 0.00 % 0.00 %

-0.07 (0%)

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A
CVGB:LSE 0.00 % 0.00 %

N/A

N/A
CAVE:LSE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.33% 79% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.33% 79% B- 80% B-
Trailing 12 Months  
Capital Gain -27.76% 51% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.76% 51% F 31% F
Trailing 5 Years  
Capital Gain -9.37% 74% C 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.37% 74% C 37% F
Average Annual (5 Year Horizon)  
Capital Gain -1.17% 49% F 40% F
Dividend Return -1.17% 49% F 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.35% 73% C 50% F
Risk Adjusted Return -3.30% 48% F 37% F
Market Capitalization 5.94B 100% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 63.66 24% 16%
Price/Book Ratio 14.65 14% 9%
Price / Cash Flow Ratio 33.55 9% 8%
Price/Free Cash Flow Ratio 33.93 7% 11%
Management Effectiveness  
Return on Equity 23.72% 97% 92%
Return on Invested Capital 10.33% 85% 77%
Return on Assets 5.98% 96% 87%
Debt to Equity Ratio 58.83% 45% 35%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.